This review highlights yttrium-90 SIRT's benefits in improving tumor response in primary hepatocellular carcinoma, suggesting enhanced outcomes through systemic therapy.
Key Points
To explore the mechanisms and clinical validation of yttrium-90 selective internal radiation therapy for primary hepatocellular carcinoma.
Review of the mechanistic foundations of yttrium-90 SIRT
Analysis of clinical evidence on its efficacy
Comparative assessment with transarterial chemoembolization
Discussion on emerging strategies and biomarker-guided regimens
Yttrium-90 SIRT enhances tumor response compared to conventional therapies
Demonstrates efficacy in downstaging tumors and improving safety profiles
Offers potential synergies with systemic therapies for advanced disease